Apremilast as an Adjuvant in Refractory Reactive Arthritis: A Retrospective Observational Study

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Reactive arthritis (ReA) is an autoimmune condition often following infection, with some patients developing chronic symptoms.
• Current treatments for ReA aim to alleviate symptoms, but curative options are lacking, and responses vary.
• Apremilast, a PDE4 inhibitor used for other inflammatory conditions, is being explored for ReA treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of oral apremilast as an add-on therapy for patients with treatment-refractory ReA.
• To assess apremilast's potential to improve disease control and reduce reliance on corticosteroids and NSAIDs.

Main Methods:

• A retrospective observational pilot study reviewed 12 adult patients with treatment-refractory ReA.
• Patients received oral apremilast (30 mg twice daily) as adjuvant therapy for 40 weeks.
• Efficacy was measured by ACR20/50/70 responses, joint counts, inflammatory markers, HAQ-DI, and corticosteroid-sparing effects.

Main Results:

• 83.33% of patients achieved ACR20 response at 40 weeks; 66.67% achieved ACR50 and 41.67% achieved ACR70.
• Significant improvements were observed in swollen and tender joint counts (79.3% and 68.8% reduction, respectively).
• 66.67% of patients reached a minimal clinically important difference in HAQ-DI; no severe adverse events were reported.

Conclusions:

• Oral apremilast demonstrates efficacy and safety as a novel adjuvant therapy for treatment-refractory ReA.
• Apremilast offers substantial improvements in joint symptoms and functional outcomes, with a notable corticosteroid-sparing effect.
• Further validation in larger, controlled trials is warranted to confirm these promising findings.